Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 11:57 ET | Source: Spherix Global Insights

Gene and Cell Therapies Emerge as Front-Runners in Neurology Innovation, with High Expectations in ALS, Parkinson’s, and Neuroimmune Disorders

EXTON, PA, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights’ latest Special Topix™: Neurology Pipeline Opportunities 2025 (US) service captures forward-looking insights from 79 U.S....
November 03, 2025 09:15 ET | Source: Cellectis Inc.

Cellectis to Present a Development Update for eti-cel at ASH 2025

Preliminary data recently shared for eti-cel (UCART20x22) show an 86% ORR and a 57% CR rate (n=7), underscoring its potential to improve outcomes in r/r NHLPreclinical data demonstrated that combining...
October 23, 2025 09:30 ET | Source: SNS Insider pvt ltd

Cancer Gene Therapy Market to Reach USD 17.35 Billion by 2032, Spread of Personalized Treatments Increasing – SNS Insider

Austin, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cancer Gene Therapy Market Size & Growth Analysis: According to SNS Insider, the global Cancer Gene Therapy Market size was valued at USD 4.07 billion...
October 22, 2025 08:00 ET | Source: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95%

SINGAPORE, Oct. 22, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing...
October 16, 2025 15:19 ET | Source: Cellectis Inc.

Le R&D Day de Cellectis souligne le potentiel de lasmé-cel pour combler un besoin médical majeur non satisfait chez les patients atteints de LAL-B en rechute ou réfractaire

○ Efficacité : taux de réponse global (ORR) de 68 % avec le Process 2 de lasmé-cel (P2) (n=22) ; 83 % à la dose recommandée de Phase 2 (RP2D, n=12) ; et 100 % dans la population cible de Phase 2...
October 16, 2025 15:19 ET | Source: Cellectis Inc.

Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL

○ Efficacy: ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9) ○ Safety: in Phase 1 (n=40), lasme-cel was generally well-tolerated...
October 16, 2025 07:00 ET | Source: Cellectis Inc.

Cellectis organise aujourd’hui son R&D Day pour présenter les avancées de son portefeuille et ses perspectives à long terme

L’ensemble des données de phase 1 et la stratégie de l’essai clinique pivot de phase 2 pour le produit candidat lasmé-cel (UCART22) dans la LAL-B en rechute ou réfractaire, seront présentées durant...
October 16, 2025 07:00 ET | Source: Cellectis Inc.

Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers

Event features full Phase 1 data and pivotal Phase 2 strategy for lasme-cel (UCART22) in r/r B-ALL NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS -...
October 14, 2025 08:00 ET | Source: CYTOMED THERAPEUTICS LIMITED

CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets

SINGAPORE, Oct. 14, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing...
October 09, 2025 12:00 ET | Source: Precedence Research

CAR-T Cell Therapy Isolator Market Outlook 2025-2034 – Insights from Towards Healthcare

Ottawa, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The growth of the CAR-T cell therapy isolator market is driven by the rising incidence of cancers and other chronic diseases, which increases the demand for...